Press release | 10th November 2008

Preclinical CRO Selects E-WorkBook Suite to Increase R&D Productivity

Guildford, UK, November 10 2008 – IDBS is proud to announce that preclinical contract research organization (CRO) PharmaLegacy Laboratories (Shanghai, China) has selected the E-WorkBook Suite to increase its R&D productivity and deliver significant competitive advantage to clients.

Providing speciality pharmacology services in oncology, bone, inflammation and immune diseases, PharmaLegacy sought a 21 CFR Part 11 compliant solution for the capture of DMPK and pharmacology data to deliver improved customer service to clients. BioBook, the advanced biology extension of the E-WorkBook Suite, will be used by PharmaLegacy scientists in Shanghai as the company continues to expand and grow its customer base. BioBook will enable the company to significantly increase client productivity and the pace of new drug development by providing effective management and analysis of complex research data.

Tom Tillotson, Vice President Corporate Planning at PharmaLegacy, commented: “We have a vision to collaborate with our clients to accelerate their research missions to develop new therapies. The E-WorkBook Suite provides us with the highest level of IP protection and regulatory compliance and will enable us to offer improved discovery, development and management capabilities to the marketplace.” He added: “The benefits will be particularly great where client organizations are utilizing the BioBook technology. BioBook will provide us with an excellent opportunity to develop long-term partnerships with biotechnology and pharmaceutical clients.”

Neil Kipling, founder and CEO of IDBS, commented: “The need for new drug candidates has resulted in an increasingly important role for CROs. To remain competitive and increase the number of successful drug candidates for clients, CROs must employ effective data management solutions. BioBook provides focused preclinical data management extension to ensure maximum productivity and will help PharmaLegacy to deliver significant competitive advantage to clients in the pharmaceutical and biotechnology industries.”

About IDBS

IDBS is a leading provider of integrated software solutions to the life sciences industry. Maximising the value of research data by enabling organisations to capture, store, share and use data efficiently and effectively, whilst protecting intellectual property across the spectrum of discovery activities.

Headquartered in Guildford, UK, IDBS has U.S. offices in California, New Jersey and Massachusetts. IDBS partners with CTC Laboratory Systems in Japan and a network of distributors to market IDBS products and services in Asia. Founded in 1989, IDBS employs more than 150 people worldwide.

About PharmaLegacy

PharmaLegacy Laboratories is a preclinical CRO providing specialty pharmacology services in Oncology, Bone, Inflammation and Immune Diseases, and Orthopaedics in Tissue Repairs and Tissue Engineering. With a vision to collaborate with our global clients to accelerate their missions to develop new therapies, PharmaLegacy provides world class services enabling much improved speed and productivity in R&D to IND/NDA/IDE endeavors of pharmaceutical/biotech/orthopaedic device companies around the world. PharmaLegacy is based in Shanghai, China.

About IDBSContact us

More news